Jinbo Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jinbo Shi has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Bin Xu
Department of Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
1 shared publication - Hai Huang
Department of General Surgery, Hangzhou TCM Hospital, Affiliated to Zhejiang Chinese Medical University, Hangzhou, China
1 shared publication Shifei Huang
Hangzhou Hospital of Traditional Chinese Medicine
1 shared publication- Wenjie Lu
Department of Hepatobiliary and Pancreatic Surgery, Second Affiliated Hospital of Zhejiang University, Hangzhou, China
1 shared publication Xiaowen Li
Hangzhou Hospital of Traditional Chinese Medicine
1 shared publication- Xin Dong
Department of Hepatobiliary Pancreatic Surgery, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, China
1 shared publication
Latest Publications
- Open Access
- 11 May 2026
- Published by Springer Nature in Research Square
Lack of Survival Benefit from Adjuvant Chemotherapy in Stage IA Pancreatic Cancer: A Propensity Score-Matched and Causal Forest Analysis
The role of adjuvant chemotherapy in stage IA (T1N0M0) pancreatic cancer remains unclear. We evaluated its survival benefit using the SEER database (2010–2022). Among 727 patients with resected stage IA disease, propensity score matching generated 241 well-balanced pairs. Chemotherapy was associated with worse overall survival (log‑rank P = 0.019) and cancer‑specific survival (P = 0.006). Subgroup analyses by age, T stage, and grade showed no benefit. A causal forest model revealed a median individual treatment effect of –2.96 months (IQR: –4.05 to 2.33 months), indicating no clinically meaningful benefit for most patients. Cross‑validation failed to confirm reliable predictive performance. Adjuvant chemotherapy was not associated with improved survival in resected stage IA pancreatic cancer, challenging its routine use and supporting a more individualized approach. Prospective validation will require multi‑institutional collaboration due to disease rarity.
- 11 May 2026
- Published by Springer Nature in Research Square
Open AccessLack of Survival Benefit from Adjuvant Chemotherapy in Stage IA Pancreatic Cancer: A Propensity Score-Matched and Causal Forest Analysis
The role of adjuvant chemotherapy in stage IA (T1N0M0) pancreatic cancer remains unclear. We evaluated its survival benefit using the SEER database (2010–2022). Among 727 patients with resected stage IA disease, propensity score matching generated 241 well-balanced pairs. Chemotherapy was associated with worse overall survival (log‑rank P = 0.019) and cancer‑specific survival (P = 0.006). Subgroup analyses by age, T stage, and grade showed no benefit. A causal forest model revealed a median individual treatment effect of –2.96 months (IQR: –4.05 to 2.33 months), indicating no clinically meaningful benefit for most patients. Cross‑validation failed to confirm reliable predictive performance. Adjuvant chemotherapy was not associated with improved survival in resected stage IA pancreatic cancer, challenging its routine use and supporting a more individualized approach. Prospective validation will require multi‑institutional collaboration due to disease rarity.
- Open Access
- 8 May 2023
- Published by Wolters Kluwer Health in Pancreas
- Vol. 52 (1) , e37-e44
Elderly Pancreatic Adenocarcinoma Cancer Patients Could Benefit From Postoperative Chemotherapy
Objectives: The study aim to investigate whether elderly patients with resectable pancreatic ductal adenocarcinoma (PDAC) could benefit from postoperative chemotherapy. Methods: This study selects the data of PDAC patients who were diagnosed between 2004 and 2014 from the Surveillance, Epidemiology, and End Results program. Median overall survival (mOS) is determined by Kaplan-Meier survival curves. Multivariate logistic regression analysis and hazard ratio are employed to assess the association among potential prognostic factors. Propensity score matching evaluation is used to reduce bias. Results: In total, there are 11,865 PDAC patients selected from the Surveillance, Epidemiology, and End Results database. Elderly PDAC patients have poor prognoses compared with younger (mOS, 15 vs 21 months). The possible reason might be that the elderly patients are less likely to receive postoperative chemotherapy. After propensity score matching, it is found that, for those who receive postoperative chemotherapy, although the mOS of older group is not as good as that of the younger group (mOS, 20 vs 23 months; 18-month survival rate: 53.4% vs 61.3%), the mOS of older group prolonged by postoperative chemotherapy is similar to that of younger group (9 vs 9 months). Conclusions: Elderly PDAC patients (≥70 years) might benefit from the currently used postoperative chemotherapy regimens.
- 8 May 2023
- Published by Wolters Kluwer Health in Pancreas
- Vol. 52 (1) , e37-e44
Open AccessElderly Pancreatic Adenocarcinoma Cancer Patients Could Benefit From Postoperative Chemotherapy
Objectives: The study aim to investigate whether elderly patients with resectable pancreatic ductal adenocarcinoma (PDAC) could benefit from postoperative chemotherapy. Methods: This study selects the data of PDAC patients who were diagnosed between 2004 and 2014 from the Surveillance, Epidemiology, and End Results program. Median overall survival (mOS) is determined by Kaplan-Meier survival curves. Multivariate logistic regression analysis and hazard ratio are employed to assess the association among potential prognostic factors. Propensity score matching evaluation is used to reduce bias. Results: In total, there are 11,865 PDAC patients selected from the Surveillance, Epidemiology, and End Results database. Elderly PDAC patients have poor prognoses compared with younger (mOS, 15 vs 21 months). The possible reason might be that the elderly patients are less likely to receive postoperative chemotherapy. After propensity score matching, it is found that, for those who receive postoperative chemotherapy, although the mOS of older group is not as good as that of the younger group (mOS, 20 vs 23 months; 18-month survival rate: 53.4% vs 61.3%), the mOS of older group prolonged by postoperative chemotherapy is similar to that of younger group (9 vs 9 months). Conclusions: Elderly PDAC patients (≥70 years) might benefit from the currently used postoperative chemotherapy regimens.